Dr. Jothydev Kesavadev was an invited faculty at the launch of Rybelsus (Semaglutide) in India, at the ‘Innovate 2022’, held in association with Indo Global Cardio Diabetes Academy and Novo Nordisk, on 15 January 2022. The program included 2 plenary sessions, chaired by Dr. V. Mohan and involved 3-panel discussions. Dr. Jothydev Kesavadev was a panellist for the panel discussion ‘Innovation: An ongoing saga in Diabetes’.